Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Unternehmen & Branche
| Name | Amneal Pharmaceuticals, Inc. |
|---|---|
| Ticker | AMRX |
| CIK | 0001723128 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 4,03 Mrd. USD |
| Beta | 1,32 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 3,018,760,000 | 72,057,000 | 0.22 | 3,678,280,000 | -70,794,000 |
| 2025-09-30 | 10-Q | 784,513,000 | 2,369,000 | 0.01 | 3,599,874,000 | -109,458,000 |
| 2025-06-30 | 10-Q | 724,508,000 | 22,417,000 | 0.07 | 3,422,788,000 | -112,118,000 |
| 2025-03-31 | 10-Q | 695,420,000 | 12,195,000 | 0.04 | 3,365,249,000 | -131,667,000 |
| 2024-12-31 | 10-K | 2,793,957,000 | -116,886,000 | -0.38 | 3,501,445,000 | -109,267,000 |
| 2024-09-30 | 10-Q | 702,468,000 | -156,000 | 0.00 | 3,460,978,000 | -93,432,000 |
| 2024-06-30 | 10-Q | 701,780,000 | 5,994,000 | 0.02 | 3,509,922,000 | -57,465,000 |
| 2024-03-31 | 10-Q | 659,191,000 | -91,643,000 | -0.30 | 3,456,397,000 | -63,724,000 |
| 2023-12-31 | 10-K | 2,393,607,000 | -83,993,000 | -0.48 | 3,472,569,000 | 19,781,000 |
| 2023-09-30 | 10-Q | 620,040,000 | 9,682,000 | 0.06 | 3,687,079,000 | 330,860,000 |
| 2023-06-30 | 10-Q | 599,046,000 | 11,917,000 | 0.08 | 3,700,886,000 | 318,169,000 |
| 2023-03-31 | 10-Q | 557,540,000 | -6,943,000 | -0.05 | 3,626,605,000 | 294,414,000 |
| 2022-12-31 | 10-K | 2,212,304,000 | -270,584,000 | -0.86 | 3,799,341,000 | 298,421,000 |
| 2022-09-30 | 10-Q | 545,557,000 | -7,613,000 | -0.02 | 3,874,039,000 | 297,469,000 |
| 2022-06-30 | 10-Q | 559,355,000 | -242,128,000 | -0.80 | 4,041,405,000 | 280,327,000 |
| 2022-03-31 | 10-Q | 497,633,000 | -8,817,000 | -0.01 | 3,888,968,000 | 391,125,000 |
| 2021-12-31 | 10-K | 2,093,669,000 | 13,163,000 | 0.07 | 3,939,664,000 | 360,340,000 |
| 2021-09-30 | 10-Q | 528,593,000 | -7,783,000 | -0.03 | 3,974,409,000 | 350,506,000 |
| 2021-06-30 | 10-Q | 535,075,000 | 29,993,000 | 0.10 | 4,023,053,000 | 346,107,000 |
| 2021-03-31 | 10-Q | 493,105,000 | 12,749,000 | 0.04 | 3,960,070,000 | 323,015,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-08-27 | Kiely John | Director | Open Market Sale | -32,000 | 9.23 | -295,360.00 | -38,1% | |
| 2025-08-25 | Shah Nikita | Officer, Executive Vice President | Open Market Sale | -6,340 | 9.50 | -60,230.00 | -7,8% | |
| 2025-08-22 | Shah Nikita | Officer, Executive Vice President | Open Market Sale | -114,492 | 9.66 | -1,105,992.72 | -142,8% | |
| 2025-08-15 | Konidaris Tasos | Officer, Executive Vice President & CFO | Open Market Sale | -219,159 | 9.43 | -2,066,669.37 | -266,9% | |
| 2025-08-14 | Konidaris Tasos | Officer, Executive Vice President & CFO | Open Market Sale | -119,206 | 9.30 | -1,108,615.80 | -143,2% | |
| 2025-08-14 | Shah Nikita | Officer, Executive Vice President | Open Market Sale | -71,694 | 9.29 | -666,037.26 | -86,0% | |
| 2025-08-13 | Konidaris Tasos | Officer, Executive Vice President & CFO | Open Market Sale | -161,365 | 9.22 | -1,487,785.30 | -192,1% | |
| 2025-08-12 | Shah Nikita | Officer, Executive Vice President | Open Market Sale | -50,000 | 9.04 | -452,000.00 | -58,4% | |
| 2025-08-12 | BOYER ANDREW S | Officer, Executive Vice President | Open Market Sale | -33,436 | 9.05 | -302,595.80 | -39,1% | |
| 2025-08-12 | Daly Jason B. | Officer, EVP, Chief Legal Officer | Open Market Sale | -22,000 | 9.05 | -199,100.00 | -25,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.